Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles

Area of Science:

• Immunology
• Molecular Biology
• Nanotechnology

Background:

• RNA interference (RNAi) offers potential for targeted therapies in immune disorders.
• Delivering small interfering RNAs (siRNAs) to primary T lymphocytes is challenging.
• CD4(+) T cells play a crucial role in various immune responses.

Purpose of the Study:

• To develop an effective method for delivering siRNAs to murine CD4(+) T cells.
• To investigate the potential of targeted lipid nanoparticles (tLNPs) for RNAi-based therapies.
• To enhance the efficacy of gene silencing in T lymphocytes.

Main Methods:

• Formulation of lipid nanoparticles (LNPs) with specific lipids for enhanced siRNA delivery.
• Surface functionalization of LNPs with anti-CD4 monoclonal antibodies for targeted delivery.
• Ex vivo and in vivo assessment of tLNP specificity and efficiency in murine models.
• Analysis of siRNA uptake, internalization, and gene silencing in CD4(+) T cells.

Main Results:

• tLNPs specifically targeted and were efficiently internalized by CD4(+) T lymphocytes ex vivo.
• Systemic administration resulted in efficient tLNP uptake in spleen, lymph nodes, blood, and bone marrow.
• Gene silencing was observed in a subset of circulating and resting CD4(+) T lymphocytes.
• tLNP internalization, not endosome escape, was identified as critical for efficacy.

Conclusions:

• Targeted lipid nanoparticles (tLNPs) provide a novel strategy for specific siRNA delivery to CD4(+) T cells.
• This approach holds promise for developing RNAi-based therapeutics for leukocyte-associated diseases.
• The findings support the potential of tLNPs in modulating T cell function for immune-related disorders.